14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AURA vs AVBP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) captures the overall head-to-head institutional edge over ArriVent BioPharma, Inc. (AVBP) on higher Unified Composite conviction (28.8/100 SELL vs. 43.7/100 HOLD) after splitting the core matrix 4–2 (led by Options & Positioning), while AVBP wins 3–1 across the 6-pillar growth and valuation breakdown. AURA trades at $7.21 (N/M Forward P/E, 0.0% operating margin) versus AVBP at $11.86 (N/M Forward P/E, -3620.0% operating margin).
Composite vs. Pillar Nuance: While AVBP currently prints a higher short-term Unified Composite Score (43.7/100 HOLD vs. AURA 28.8/100 SELL), AURA captures the overall institutional head-to-head verdict (4–2 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3620.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7); meanwhile AVBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs AVBP. Trailing 12-month operating profitability (AURA 0.0% vs AVBP -3620.0%) and valuation multiples (AURA N/M vs AVBP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $676.0M market capitalization and -3620.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AURA vs AVBP Key Questions & Quantitative Answers
As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) captures the overall head-to-head institutional edge over ArriVent BioPharma, Inc. (AVBP) on higher Unified Composite conviction (28.8/100 SELL vs. 43.7/100 HOLD) after splitting the core matrix 4–2 (led by Options & Positioning), while AVBP wins 3–1 across the 6-pillar growth and valuation breakdown. AURA trades at $7.21 (N/M Forward P/E, 0.0% operating margin) versus AVBP at $11.86 (N/M Forward P/E, -3620.0% operating margin). Composite vs. Pillar Nuance: While AVBP currently prints a higher short-term Unified Composite Score (43.7/100 HOLD vs. AURA 28.8/100 SELL), AURA captures the overall institutional head-to-head verdict (4–2 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3620.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7); meanwhile AVBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AURA and AVBP split Growth & Scale metrics: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AVBP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $5.0M TTM revenue (100.0% gross margin, -3620.0% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus $5.0M for AVBP. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVBP.
AVBP screens cheaper on headline valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AVBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 112.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus AVBP (-48.7% ROE) capital efficiency.
In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, AVBP carries 88.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.26β · 127% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.